Teva Reports 25% Increase In Q3 Net Sales

Teva Pharmaceutical (Teva) reported a profit of $649m for the third quarter of 2009, compared with $631m in third quarter of 2008. The company reported net sales of $3,550m, an increase of 25%, compared to $2,842m in the third quarter, prior year.

The company reported an operating income of $997m, an increase of 42%,compared to the same period, prior year. GAAP operating income totaled $753m, compared with $622m.

Shlomo Yanai, president and CEO of Teva, said: “This was another very strong quarter for Teva, with record-breaking financial results across the board. In fact, for the first time, we crossed the billion dollar mark in quarterly cash flow from operations. All of our business units and geographies continued to grow during the quarter, with especially strong sales of Copaxone.

“This is the time of year when we develop our workplan and update our strategy for the next few years. The process this year is an especially inspiring one, as the more closely we analyse the opportunities ahead, the more excited we become about Teva’s future which, in both the near and long-term, looks very bright.”